JT Stratford LLC Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN

JT Stratford LLC lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 39.4% during the third quarter, HoldingsChannel.com reports. The firm owned 1,710 shares of the biopharmaceutical company’s stock after selling 1,113 shares during the period. JT Stratford LLC’s holdings in Regeneron Pharmaceuticals were worth $961,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $34,000. Traub Capital Management LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $38,000. Finally, E Fund Management Hong Kong Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research reports. Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Evercore lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. Canaccord Genuity Group lifted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Finally, Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $796.52.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 5,274 shares of company stock valued at $4,142,738 over the last three months. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $764.93 on Friday. The stock has a market cap of $80.87 billion, a price-to-earnings ratio of 18.41, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The business has a fifty day moving average of $771.31 and a two-hundred day moving average of $686.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the company earned $12.07 EPS. The company’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were issued a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.